CM326

BIOLOGICAL10 trials

Conditions

AsthmaAtopic DermatitisChronic Rhinosinusitis With Nasal PolypsHealthyModerate to Severe AsthmaModerate-to-severe Atopic Dermatitis

Phase 1

Single Ascending Dose Study of CM326 in Healthy Volunteers

CompletedNCT04842201

Keymed Biosciences Co.LtdAsthma

Start: 2021-04-13End: 2021-09-28Updated: 2022-04-12

A Multiple Ascending Doses Study of CM326 Injection in Healthy Subjects

CompletedNCT05171348

Keymed Biosciences Co.LtdAsthma

Start: 2022-01-07End: 2022-10-11Updated: 2023-06-22

The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis

NCT05186922

Keymed Biosciences Co.LtdModerate-to-severe Atopic Dermatitis

Start: 2022-02-17End: 2023-01-31Target: 54Updated: 2022-03-09

A Study of CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps

CompletedNCT05324137

Keymed Biosciences Co.LtdChronic Rhinosinusitis With Nasal Polyps

Start: 2022-07-11End: 2024-03-29Updated: 2024-11-08

Study of CM326 Injection in Healthy Subjects

CompletedNCT05715333

Keymed Biosciences Co.LtdHealthy

Start: 2023-03-21End: 2023-10-04Updated: 2024-11-08

Phase 2

The Study of CM326 in Adult Subjects With Atopic Dermatitis

NCT05671445

Keymed Biosciences Co.LtdAtopic Dermatitis

Start: 2023-02-09End: 2025-03-28Target: 100Updated: 2023-08-01

The Study of CM326 in Moderate-to-severe Atopic Dermatitis

NCT05671432

Keymed Biosciences Co.LtdModerate-to-severe Atopic Dermatitis

Start: 2022-12-27End: 2024-12-30Target: 240Updated: 2023-01-04

A Study of CM326 in Subjects With Moderate to Severe Asthma

NCT05774340

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Moderate to Severe Asthma

Start: 2023-05-18End: 2025-01-31Target: 207Updated: 2023-12-15

Study of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis

Not yet recruitingNCT06372678

Keymed Biosciences Co.LtdChronic Rhinosinusitis With Nasal Polyps

Start: 2024-06-30End: 2026-06-30Target: 90Updated: 2024-04-18

Phase 3

A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma

RecruitingNCT07372287

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Moderate to Severe Asthma

Start: 2026-01-23End: 2029-03-31Target: 230Updated: 2026-04-28

Related Papers

An anti-TSLP monoclonal antibody for uncontrolled CRSwNP: the DUBHE randomized clinical trial.

2025-09-291 citations

Translational Investigation of CM326 from Preclinical Studies to Randomized Phase I Clinical Trials in Healthy Adults.

2025-04-041 citations

Anti-thymic stromal lymphopoietin monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps (DUBHE): Rationale and design of a multicenter, randomized, double-blind, placebo-controlled study

Asia Pacific Allergy2024-01-258 citations